2
|
Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jett JR, Mandrekar SJ, Schild SE. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7547] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7547 Background: Sorafenib is a multikinase inhibitor with single-agent activity in previously treated NSCLC. In an effort to evaluate its single agent activity in previously untreated NSCLC, the NCCTG undertook a front-line “window of opportunity” study. Materials and Methods: Patients with stage IIIB (pleural effusion) or stage IV NSCLC received sorafenib dosed at 400 mg BID continuously, with a cycle defined as 4 weeks. Patients were evaluated weekly during the first 2 cycles with those who progressed rapidly going on to receive standard chemotherapy. Based on a two-stage Fleming design, if only at most 1 confirmed response was observed in the first 20 patients enrolled to stage I, the regimen would be considered ineffective. If 2 or more responses were observed, the study would proceed to stage 2 and accrue an additional 22 patients. If 5 or more confirmed responses were observed, the regimen would be recommended for further testing. Results: The study did not meet the stage I efficacy criteria (only 1 confirmed partial response in the first 20 patients) and was permanently closed after enrolling 25 evaluable patients [15 females, 10 males; 4 stage IIIB, 21 stage IV; median age 67 (45–85)]. 2 patients are still receiving treatment (14 and 15 months). No grade 3 or higher hematologic adverse events were observed. Thirteen (52%) patients had a grade 3 non-hematologic adverse event with fatigue (20%), diarrhea (8%), and dyspnea (8%) being the most common. There was one grade 4 pulmonary hemorrhage. A total of 3 (12%) PRs; and 7 (28%) SD were observed in the 25 patients 7 (28%) patients were progression- free at 24 weeks. Median survival and median time to progression were 8.8 and 2.9 months respectively. Conclusion: While the pre- specified efficacy endpoints were not met, the objective response rate of 12% and median survival of 8.8 months suggest that single agent sorafenib has activity similar to two-drug combinations. The feasibility and utility of the “window of opportunity” design in estimating the activity of novel compounds was demonstrated. Finally, the single-agent activity of sorafenib argues for combination studies with standard chemotherapy agents. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. A. Adjei
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - J. R. Molina
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. L. Hillman
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - R. F. Luyun
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - N. F. Reuter
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - K. M. Rowland
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - J. R. Jett
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. J. Mandrekar
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. E. Schild
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| |
Collapse
|
3
|
Hammack JE, Mailliard JA, Loprinzi CL, Rospond RM, O'Fallon JR, Wilwerding MB, Reuter NF, Michalak JC, Fidler P, Miser AW. Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage 1996; 12:234-40. [PMID: 8898507 DOI: 10.1016/0885-3924(96)00191-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We performed an open-label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients, all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 micrograms/hr or 50 micrograms/hr fentanyl transdermal patch depending on prior opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities, and use of rescue medication were also assessed. There was a 24%-29% reduction in mean VAS and CAT pain scores as compared with the baseline and a 25% increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46% of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of all study patients were not at all satisfied with the pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 micrograms/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.
Collapse
|
4
|
Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer 1996; 77:2520-8. [PMID: 8640701 DOI: 10.1002/(sici)1097-0142(19960615)77:12<2520::aid-cncr15>3.0.co;2-u] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND This prospective trial was conducted to evaluate the outcome of patients treated with preoperative and post operative chemotherapy, mastectomy, and irradiation for locoregionally advanced breast carcinoma. METHODS Between June 1986 and September 1990, 71 patients received 2 cycles of doxorubicin that alternated with 2 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil prior to mastectomy; irradiation was administered when the tumor was not amenable to surgical resection. Additional chemotherapy and tamoxifen, in hormone receptor-positive tumors, was used after mastectomy. Post-operative irradiation was given on a selective basis for patients at high risk for locoregional disease recurrence. RESULTS Although 5 patients (7%) had disease progression, clinical partial or complete tumor response to preoperative chemotherapy was noted in 46 patients (65%). Sixty-eight patients (96%) underwent mastectomy. With a median follow-up of 52 months, the relapse-free and overall survival rates at 5 years were 42% and 57% respectively. Locoregional tumor recurrence occurred in 14 patients (20%), and 28 patients (39%) developed metastatic disease. Menopausal status, clinical presentation (noninflammatory vs. inflammatory), and American Joint Committee on Cancer clinical stage were independent covariates associated with patient outcome. CONCLUSIONS Preoperative alternating chemotherapy, with the selective use of irradiation, resulted in significant locoregional disease regression and the successful integration of mastectomy into the therapeutic strategy. Locoregional tumor control and relapse-free and overall survival estimates for the approach described herein compared favorably with other comtemporary reports for this condition.
Collapse
Affiliation(s)
- T M Pisansky
- Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Hestorff RD, Chong SF, Reuter NF, Shanahan TG. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13:2856-9. [PMID: 7595749 DOI: 10.1200/jco.1995.13.11.2856] [Citation(s) in RCA: 140] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia. PATIENTS AND METHODS Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of > or = 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. RESULTS Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. CONCLUSION This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.
Collapse
Affiliation(s)
- R M Goldberg
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM, Ellison NM, Reuter NF, Nelimark RA. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer 1990; 65:418-21. [PMID: 2297632 DOI: 10.1002/1097-0142(19900201)65:3<418::aid-cncr2820650307>3.0.co;2-k] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A prospective clinical trial was done to evaluate the efficacy and toxicity of cisplatin plus etoposide (VP-16) in patients with breast cancer who failed one previous chemotherapy regimen for advanced disease or relapsed within 12 months of adjuvant chemotherapy. Partial responses occurred in 11 of 44 evaluable patients (25%; 95% confidence interval (CI), 13% to 40%). The median time to disease progression in responding patients was 4 months (range, 3 to 6+ months), whereas the median time to disease progression and survival for all patients who were treated were 3 and 7 months, respectively. There was marked toxicity related to this protocol treatment including pancytopenia, gastrointestinal upset, and renal insufficiency. Two treatment-related deaths occurred; one from sepsis and one from renal failure. Thus, this regimen, as second-line chemotherapy for women with metastatic breast cancer, resulted in moderate, short-term, antitumor activity at the expense of marked toxicity.
Collapse
|
7
|
Ingle JN, Pfeifle DM, Green SJ, Kvols LK, Brunk SF, Reuter NF, Krook JE, Laurie JA, Everson LK, Marschke RF. Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. Am J Clin Oncol 1985; 8:275-82. [PMID: 3909798 DOI: 10.1097/00000421-198508000-00001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
One hundred fifty-one women with advanced breast cancer who had failed prior chemotherapy were randomized to monthly courses of doxorubicin (60 mg/m2 I.V. day 1, observation after 500 mg/m2) or doxorubicin (40 mg/m2 I.V. day 1; maximum 500 mg/m2) and mitolactol (135 mg/m2 orally, days 1-10; 180 mg/m2 after maximum doxorubicin). Median survival times were 232 days for doxorubicin and 225 days for doxorubicin + mitolactol, and median times to progression were 112 days and 97 days, respectively. Results are inconsistent with a 25% improvement in survival or time to progression for doxorubicin + mitolactol (p = 0.04 and 0.02, respectively, adjusted for stratification factors but not multiple testing). Regression rates for all patients, both measurable and evaluable, were 30% for doxorubicin alone and 26% for doxorubicin + mitolactol. Regression rates were significantly higher in patients with measurable indicator lesions. Cardiac toxicity was seen in four patients, all of whom were receiving doxorubicin alone. It appears that the combination of doxorubicin + mitolactol is not substantially more effective than doxorubicin alone in women with advanced breast cancer and prior chemotherapy exposure.
Collapse
|